Month: February 2023

Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. was written by Gharib, Khalil El;Macaron, Walid;Kattan, Joseph;Salloum, Mohamad Ali;Farhat, Fadi;Smith, Marianne;Karak, Fadi El. And the article was included in Current problems in cancer in 2022.Computed Properties of C24H29N7O2 This article mentions the following:

CDK 4/6 inhibitors have been yielding propitious results when with hormone therapy in the management of Her2-negative and hormone-receptor (HR)-positive metastatic breast cancer, palbociclib being one of the first molecules investigated in this setting. However, the response to CDK4/6 inhibitors is variable. To identify predictive and prognostic factors of response to this therapeutic regimen. Eligible patients were females with HR+ and Her2- advanced breast cancer, receiving Palbociclib in combination with Letrozole. PFS was the primary endpoint in the evaluation of response to treatment. This survival was then further segregated according to various characteristics: histological (type, grade, hormone receptors), metastatic site, line of treatment, response type at initial assessment, and best response achieved. The data was then processed by two statistical analysis models: Kaplan-Meier and univariate preceding multivariate Cox proportional risks. Sixty patients were included and followed for a median follow-up duration of 15.98 months. PFS recorded a median of 19.07 months (95% CI=15.43-22.71). PFS had a median of 12.99 months in the absence of progesterone receptors (vs 20.05 months in the case of positive estrogen and progesterone receptors; P聽=聽0.046), a median of 13.02 months in the presence of liver metastases (vs 22.98 months in the absence of liver metastases; P聽=聽0.007), and 15.94 months in the case of second-line and beyond (vs 22.98 months in the case of first-line; P聽=聽0.033). Regarding the Hazard Ratio of progression, we note age (HR 0.941; P聽=聽0.019), liver metastases (HR 2.751; P聽=聽0.051), response at initial evaluation (HR<1; P < 0.001) and best response (HR<1; P聽=聽0.003). PFS reached similar figures to those of international studies. The absence of progesterone receptors, presence of liver metastases, and use as second-line or beyond are associated with a reduced median PFS. One year age increase (protective factor), liver metastases (risk factor), response at initial evaluation, and best response achieved are identified as the most predictive factors of the response to this treatment regimen and of the progression risk. In the experiment, the researchers used many compounds, for example, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2Computed Properties of C24H29N7O2).

6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Computed Properties of C24H29N7O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Overall Shape Constraint of Alternating 伪/尾-Hybrid Peptides Containing Bicyclic 尾-Proline was written by Wang, Siyuan;Otani, Yuko;Zhai, Luhan;Su, Aoze;Nara, Masayuki;Kawahata, Masatoshi;Yamaguchi, Kentaro;Sada, Akane;Ohki, Rieko;Ohwada, Tomohiko. And the article was included in Organic Letters in 2019.Formula: C30H30Cl2N4O4 This article mentions the following:

Our NMR, IR/Raman, CD spectroscopic, and X-ray crystallog. studies, as well as accelerated mol. dynamics simulations, showed that alternating hybrid 伪/尾-peptides containing a bicyclic 尾-proline surrogate form unique extended curved folds, regardless of the peptide length and solvent environment. It is suggested that extended 尾/PPII structures are preferred in the insulating 伪-alanine moieties between the rigid bicyclic 尾-proline structures. These hybrid peptides inhibit p53-MDM2 and p53-MDMX protein-protein interactions. In the experiment, the researchers used many compounds, for example, 4-(cis-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one (cas: 548472-68-0Formula: C30H30Cl2N4O4).

4-(cis-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one (cas: 548472-68-0) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).Formula: C30H30Cl2N4O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Effects of 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (KB-2796) on cerebral circulation in dogs was written by Morita, Tominori;Iwamoto, Takahiro;Harada, Kengo;Hara, Hideaki;Sukamoto, Takayuki;Ito, Keizo;Nurimoto, Seiichi. And the article was included in Oyo Yakuri in 1993.Application of 101477-54-7 This article mentions the following:

The effects of 1-[bis(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (KB-2796, I), a new calcium antagonist, on cerebral circulation were studied in anesthetized dogs. KB-2796 increased the vertebral blood flow when injected into the vertebral artery (3-300 渭g/kg) or into the vein (30-1,000 渭g/kg) or introduced into the duodenum (3 or 10 mg/kg) in anesthetized dogs. KB-2796 was more potent than flunarizine and papaverine in increasing the flow rate. The duration of action of KB-2796 was longer than that of papaverine and compatible to that of flunarizine. The effect of KB-2796 injected into the vertebral artery in increasing the vertebral blood flow was not affected by pretreatment with propranolol, atropine, chlorpheniramine or aminophylline in anesthetized dogs. Furthermore, KB-2796 (i.v.) did not potentiate the effect of adenosine. KB-2796 (0.1 and 0.3 mg/kg, i.v.) and flunarizine (1 mg/kg, i.v.) increased the cerebral blood flow without modifying cerebral oxygen consumption in pancronium-immobilized anesthetized dogs. The results suggest that KB-2796 increases the cerebral blood flow presumably through vasodilation of the cerebral vessels by blocking calcium channels. In the experiment, the researchers used many compounds, for example, 1-(Bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (cas: 101477-54-7Application of 101477-54-7).

1-(Bis(4-fluorophenyl)methyl)-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride (cas: 101477-54-7) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 掳C and boils at 125鈥?30 掳C. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Application of 101477-54-7

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Health effects and risks associated with the occurrence of pharmaceuticals and their metabolites in marine organisms and seafood was written by Madikizela, Lawrence Mzukisi;Ncube, Somandla. And the article was included in Science of the Total Environment in 2022.SDS of cas: 98105-99-8 This article mentions the following:

Pharmaceuticals and their metabolites are continuously invading the marine environment due to their input from the land such as their disposal into the drains and sewers which is mostly followed by their transfer into wastewater treatment plants (WWTPs). Their incomplete removal in WWTPs introduces pharmaceuticals into oceans and surface water. To date, various pharmaceuticals and their metabolites have been detected in marine environment. Their occurrence in marine organisms raises concerns regarding toxic effects and development of drug resistant genes. Therefore, it is crucial to review the health effects and risks associated with the presence of pharmaceuticals and their metabolites in marine organisms and seafood. This is an important study area which is related to the availability of seafood and its quality. Hence, this study provides a critical review of the information available in literature which relates to the occurrence and toxic effects of pharmaceuticals in marine organisms and seafood. This was initiated through conducting a literature search focussing on articles investigating the occurrence and effects of pharmaceuticals and their metabolites in marine organisms and seafood. In general, most studies on the monitoring of pharmaceuticals and their metabolites in marine environment are conducted in well developed countries such as Europe while research in developing countries is still limited. Pharmaceuticals present in freshwater are mostly found in seawater and marine organisms. Furthermore, the toxicity caused by different pharmaceutical mixtures was observed to be more severe than that of individual compounds In the experiment, the researchers used many compounds, for example, 6-Fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 98105-99-8SDS of cas: 98105-99-8).

6-Fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 98105-99-8) belongs to piperazine derivatives. Piperazine belongs to the family of medicines called anthelmintics. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).SDS of cas: 98105-99-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Palbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase was written by Fujii, Tomoyasu;Kamishikiryo, Jun;Morita, Tetsuo. And the article was included in Pharmacological Reports in 2022.SDS of cas: 571190-30-2 This article mentions the following:

Lipoprotein metabolism is essential for the growth and proliferation of cancer cells, and is involved in the supply of energy and cellular components. Lipoprotein lipase (LPL) is a very important enzyme in lipoprotein metabolism; however, the details underlying the mechanism of LPL secretion are unclear. Palbociclib is an antitumor drug that inhibits cell cycle progression and suppresses the growth of cancer cells. The effects of palbociclib on energy metabolism, particularly on lipid metabolism, have not been fully elucidated. We examined the regulation of LPL secretion, which is primarily involved in lipoprotein metabolism FM3A mouse mammary tumor cells, which are hormone receptor-pos. breast cancer cells, were treated with palbociclib, and the activity and protein levels of secreted LPL were measured. Moreover, the changes in intracellular lipid content were measured by fluorescence staining using Nile Red. FM3A cells were treated with palbociclib, the activity and protein content of secreted LPL were increased. The stimulatory secretion of LPL by palbociclib was suppressed by an intracellular Ca²⁺ chelator (BAPTA-AM) and a Ca²⁺/calmodulin-dependent protein kinase kinase (CaMKK) inhibitor (STO-609). Furthermore, the palbociclib-stimulated secretion of LPL was not observed in AMP-activated protein kinase (AMPK)-knockdown cells. An increase in the fluorescence intensity of Nile Red was observed in palbociclib-treated cells; however, no increase was observed in LPL-knockdown cells. Our data suggest that palbociclib causes intracellular lipid accumulation in breast cancer cells by stimulating Ca²⁺/CaMKK/AMPK-mediated LPL secretion. In the experiment, the researchers used many compounds, for example, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2SDS of cas: 571190-30-2).

6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Two common salts in the form of which piperazine is usually prepared for pharmaceutical or veterinary purposes are the citrate, 3C4H10N2.2C6H8O7 (i.e. containing 3 molecules of piperazine to 2 molecules of citric acid), and the adipate, C4H10N2.C6H10O4 (containing 1 molecule each of piperazine and adipic acid).SDS of cas: 571190-30-2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Design, Synthesis, and Antibacterial Evaluation of Propylene-tethered 8-Methoxyl Ciprofloxacin-isatin Hybrids was written by Guo, Hua. And the article was included in Journal of Heterocyclic Chemistry in 2018.Application of 112811-57-1 This article mentions the following:

A series of 8-methoxyl ciprofloxacin (8-OMe CPFX)-isatin hybrids tethered through propylene were designed, synthesized, and examined for their in vitro antibacterial activities against a panel of Gram-pos. and Gram-neg. pathogens including drug-resistant bacteria. All the synthesized hybrids (min. inhibitory concentration: 鈮?.03-64 渭g/mL) exhibited considerable activities against the tested strains, especially against the Gram-neg. pathogens. Among them, hybrid 11-Cyclopropyl-6-fluoro-8-methoxy-7-(4-(3-(5-methyl-2,3-dioxoindolin-1-yl)propyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid was no inferior to the parent 8-OMe CPFX that could act as a starting point for further optimization. In the experiment, the researchers used many compounds, for example, 1-Cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 112811-57-1Application of 112811-57-1).

1-Cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 112811-57-1) belongs to piperazine derivatives. Simple N-substituted piperazines have been found in many drug molecules. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Application of 112811-57-1

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Metformin reverse minocycline to inhibit minocycline-resistant Acinetobacter baumannii by destroy the outer membrane and enhance membrane potential in vitro was written by Guo, Tingting;Sun, Xiaoli;Yang, Jie;Yang, Liying;Li, Mengying;Wang, Yuhang;Jiao, Hongmei;Li, Guocai. And the article was included in BMC Microbiology in 2022.Product Details of 85721-33-1 This article mentions the following:

Acinetobacter baumannii (A. baumannii) is an opportunistic pathogen and has emerged as one of the most troublesome pathogens. Drug resistance in A. baumannii has been reported on a global scale. Minocycline was found to be active against multi-drug resistant A. baumannii and was approved by the FDA for the infections caused by sensitive strains of A. baumannii. However, the emergence of minocycline resistance and its toxic effects still need to be addressed. Therefore, this study aimed to evaluate the synergistic effects of metformin combined with minocycline on minocycline-resistant A. baumannii. The effect of metformin on the antibacterial activity of minocycline was determined by checkerboard and time-killing assay. Further, it was observed by biofilm formation assay that metformin combination with minocycline can inhibit the formation of biofilm. Outer membrane integrity, membrane permeability, membrane potential and reactive oxygen species (ROS) were monitored to explore the underlying synergistic mechanisms of metformin on minocycline. And the results shown that metformin can destroy the outer membrane of A. baumannii, enhance its membrane potential, but does not affect the membrane permeability and ROS. These findings suggested that the combination of metformin and minocycline has the potential for rejuvenating the activity of minocycline against minocycline-resistant A. baumannii. In the experiment, the researchers used many compounds, for example, 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 85721-33-1Product Details of 85721-33-1).

1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid (cas: 85721-33-1) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 掳C and boils at 125鈥?30 掳C. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Product Details of 85721-33-1

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas was written by Bi, Chengfeng;Zhang, Xuan;Lu, Ting;Zhang, Xiaoyan;Wang, Xianhuo;Meng, Bin;Zhang, Huilai;Wang, Ping;Vose, Julie M.;Chan, Wing C.;McKeithan, Timothy W.;Fu, Kai. And the article was included in Haematologica in 2017.Reference of 1255517-76-0 This article mentions the following:

Mechanistic target of rapamycin (mTOR) complex 1 is a central integrator of nutrient and growth factor inputs that controls cell growth in eukaryotes. The second generation of mTOR kinase inhibitors (TORKi), directly targeting the mTOR catalytic site, are more effective than rapamycin and its analogs in cancer treatment, particularly in inducing apoptosis. However, the mechanism underlying the cytotoxic effect of TORKi remains elusive. Herein, we demonstrate that TORKi-induced apoptosis is predominantly dependent on the loss of mTOR complex 1-mediated 4EBP activation. Knocking out RICTOR, a key component of mTOR complex 2, or inhibiting p70S6K has little effect on TORKi-induced apoptosis. Conversely, increasing the eIF4E:4EBP ratio by either overexpressing eIF4E or knocking out 4EBP1/2 protects lymphoma cells from TORKi-induced cytotoxicity. Furthermore, downregulation of MCL1 expression plays an important role in TORKi-induced apoptosis, whereas BCL-2 overexpression confers resistance to TORKi treatment. We further show that the therapeutic effect of TORKi in aggressive B-cell lymphomas can be predicted by BH3 profiling, and improved by combining it with pro-apoptotic drugs, especially BCL-2 inhibitors, both in vitro and in vivo. Taken together, the study herein provides mechanistic insight into TORKi cytotoxicity and identified a potential way to optimize its efficacy in the clin. treatment of aggressive B-cell lymphoma. In the experiment, the researchers used many compounds, for example, 2-((4-(5-Ethylpyrimidin-4-yl)piperazin-1-yl)methyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole (cas: 1255517-76-0Reference of 1255517-76-0).

2-((4-(5-Ethylpyrimidin-4-yl)piperazin-1-yl)methyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole (cas: 1255517-76-0) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 掳C and boils at 125鈥?30 掳C. Piperazine and its salts did not induce point mutations in a bacterial test. A series of mutagenicity studies in cells, both in vitro and in vivo, has been completed and showed no evidence of mutagenic effect.Reference of 1255517-76-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Radioimmunoassay of tricyclic antidepressant and some phenothiazine drugs in forensic toxicology was written by Robinson, Katherine;Smith, R. N.. And the article was included in Journal of Immunoassay in 1985.Application In Synthesis of N,N-Dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine-2-sulfonamide This article mentions the following:

A RIA for screening blood and urine for tricyclic antidepressant and some phenothiazine drugs in forensic toxicol. is described. The assay has a broad cross-reactivity that enables therapeutic or subtherapeutic levels of most tricyclic antidepressants and a number of phenothiazines in blood to be detected. The antiserum is com. available and the radioligand, a radioiodinated conjugate of N-acetyl-L-histidine and nortriptyline聽聽[72-69-5], are easily prepared Blood samples required prior extraction to reduce the background but urine may be assayed directly. Seventy five 渭L of blood or 100 渭L of urine are required. Hemolysis or decomposition of the samples, common anticoagulants, and NaF do not affect the results. Data for 57 compounds are presented. In the experiment, the researchers used many compounds, for example, N,N-Dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine-2-sulfonamide (cas: 316-81-4Application In Synthesis of N,N-Dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine-2-sulfonamide).

N,N-Dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine-2-sulfonamide (cas: 316-81-4) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Application In Synthesis of N,N-Dimethyl-10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine-2-sulfonamide

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Mode of insertion of miconazole, ketoconazole and deacylated ketoconazole in lipid layers. A conformational analysis was written by Brasseur, R.;Vandenbosch, C.;Van den Bossche, H.;Ruysschaert, J. M.. And the article was included in Biochemical Pharmacology in 1983.SDS of cas: 67914-61-8 This article mentions the following:

The conformation of three imidazole derivatives, miconazole, ketoconazole and deacylated ketoconazole (R 39519) inserted in a lipid layer was calculated using a procedure of conformational anal. For each imidazole derivative all probable conformers were inserted into a dipalmitoyl phosphatidylcholine (DPPC) monolayer. Miconazole maintains its two dichlorophenyl groups in the hydrophobic phase whereas the imidazole moiety is orientated in the hydrophilic phase. Ketoconazole orientates in dichlorophenyl group in the hydrophobic phase whereas its acylated piperazine moiety is oriented towards the hydrophobic region. Deacylation inverses completely the orientation of the compound The most probable conformer of R 39519 is inserted in the lipid layer with its piperazine moiety orientated towards the aqueous phase. The inversion increases the area occupied per drug mol. from 30 脜² for ketoconazole to 90 脜² for R39519 equal to the mean area occupied per miconazole mol. and higher than that occupied per DPPC mol. (60 脜²). Such a conformation should result in a destabilizing effect of microconazole and R 39519; this was proved using differential scanning calorimetry. In the experiment, the researchers used many compounds, for example, rel-1-(4-(((2R,4S)-2-((1H-Imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine (cas: 67914-61-8SDS of cas: 67914-61-8).

rel-1-(4-(((2R,4S)-2-((1H-Imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine (cas: 67914-61-8) belongs to piperazine derivatives. The piperazine scaffold is often found in biologically active compounds in different therapeutic areas. These therapeutic areas include antifungals, antidepressants, antivirals, and serotonin receptor (5-HT) antagonists/agonists. Although many piperazine derivatives occur naturally, piperazine itself can be synthesized by reacting alcoholic ammonia with 1,2-dichloroethane, by the action of sodium and ethylene glycol on ethylene diamine hydrochloride, or by reduction of pyrazine with sodium in ethanol.SDS of cas: 67914-61-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics